Floatz logo

Zn-C3

Unresectable Malignant Solid Neoplasm

National Cancer Institute (NCI)Phase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

58 Active assets in the Unresectable Malignant Solid Neoplasm cohort.

Asset / SponsorPhaseRating
Nivolumab
Fred Hutchinson Cancer Center
Phase 2B
Herzuma
National Cancer Institute (NCI)
Phase 2B
Talzenna
National Cancer Institute (NCI)
Phase 2B
Olaparib
National Cancer Institute (NCI)
Phase 2B
Bet Bromodomain Inhibitor Zen-3694
National Cancer Institute (NCI)
Phase 2B

View all 50 →

Same molecule, other indications

Zn-C3 is also rated in:

ovarian cancerDormant
CCC
Indicative ·
53 / 100
View asset →
primary peritoneal carcinomaDormant
CCC
Indicative ·
51 / 100
View asset →
fallopian tube cancerDormant
CC
Indicative ·
47 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →